camostat has been researched along with Hypertrophy in 12 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " To test this concept, we investigated the effects of three potentially inhibitory substances on rat pancreatic hypertrophy caused by feeding of camostate over 2 weeks: (1) L-364,718, the novel specific highly potent nonpeptide CCK receptor antagonist, (2) octreotide (SMS 201-995), a potent long-lasting somatostatin analogue and (3) pancreastatin (33-49), the biologically active C-terminal fragment of the novel gastrointestinal peptide pancreastatin." | 7.67 | Influence of CCK antagonist L-364,718, pancreastatin (33-49) and a somatostatin analogue on camostate-induced rat pancreatic hypertrophy. ( Choudhury, AR; Creutzfeldt, W; Fölsch, UR; Nustede, R; Schmidt, WE; Siegel, EG; Stöckmann, F; Wilms, HM, 1989) |
| " To test this concept, we investigated the effects of three potentially inhibitory substances on rat pancreatic hypertrophy caused by feeding of camostate over 2 weeks: (1) L-364,718, the novel specific highly potent nonpeptide CCK receptor antagonist, (2) octreotide (SMS 201-995), a potent long-lasting somatostatin analogue and (3) pancreastatin (33-49), the biologically active C-terminal fragment of the novel gastrointestinal peptide pancreastatin." | 3.67 | Influence of CCK antagonist L-364,718, pancreastatin (33-49) and a somatostatin analogue on camostate-induced rat pancreatic hypertrophy. ( Choudhury, AR; Creutzfeldt, W; Fölsch, UR; Nustede, R; Schmidt, WE; Siegel, EG; Stöckmann, F; Wilms, HM, 1989) |
| "Chronic feeding of rats with camostate results in pancreatic hypertrophy or hyperplasia, or both." | 3.67 | Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas. ( McLaughlin, RE; Ozawa, S; Renner, IG; Rich, KA; Wisner, JR, 1988) |
| "Chronic oral administration of camostate, a specific serine protease inhibitor, is known to induce pancreas hypertrophy in rats." | 3.67 | [Effect of a specific serine protease inhibitor on the rat pancreas. II. Influence of camostate on the endocrine pancreas]. ( Creutzfeldt, W; Göke, B; Lankisch, PG; Siegel, EG; Stöckmann, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yonezawa, H | 1 |
| Kisfalvi, K | 1 |
| Varga, G | 1 |
| Papp, M | 1 |
| Hajnal, F | 1 |
| Friess, H | 1 |
| Büchler, M | 1 |
| Kogire, M | 1 |
| Inoue, K | 1 |
| Gu, Y | 1 |
| Uchida, K | 1 |
| Imamura, M | 1 |
| Ishikawa, T | 1 |
| Kanno, T | 2 |
| Herzig, KH | 1 |
| May, D | 1 |
| Louie, DS | 1 |
| Takahashi, T | 1 |
| Göke, B | 3 |
| Owyang, C | 1 |
| Koop, I | 1 |
| Lindenthal, M | 1 |
| Schade, M | 1 |
| Trautmann, M | 1 |
| Adler, G | 2 |
| Arnold, R | 2 |
| Terasawa, K | 1 |
| Wereszczyńska-Siemiatkowska, U | 1 |
| Pohl, U | 1 |
| Otto, J | 1 |
| Lankisch, PG | 2 |
| Schmidt, WE | 1 |
| Stöckmann, F | 2 |
| Choudhury, AR | 1 |
| Wilms, HM | 1 |
| Siegel, EG | 2 |
| Nustede, R | 1 |
| Fölsch, UR | 1 |
| Creutzfeldt, W | 2 |
| Fenchel, K | 1 |
| Knobloch, S | 1 |
| Wisner, JR | 1 |
| McLaughlin, RE | 1 |
| Rich, KA | 1 |
| Ozawa, S | 1 |
| Renner, IG | 1 |
12 other studies available for camostat and Hypertrophy
| Article | Year |
|---|---|
Secretory responses of hypertrophied rat pancreas induced by repeated oral administrations of a synthetic protease inhibitor.
Topics: Acetylcholine; Administration, Oral; Animals; Cholecystokinin; Esters; Gabexate; Guanidines; Hypertr | 1983 |
Alcohol does not affect the trophic pancreatic effect of CCK and its plasma level in young rats.
Topics: Animals; Cholecystokinin; Esters; Ethanol; Gabexate; Guanidines; Hypertrophy; Male; Pancreas; Rats; | 1994 |
Chronic effects of camostate on growth and endocrine function of the pancreas in streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Esters; Gabexate; Guanidines; Hyperplasia; Hy | 1993 |
Dissociation of CCK-8-induced fluid secretion from protein secretion by ion-transport blockers in rat pancreas.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; Amiloride; Animals; Esters; Furosemide; | 1992 |
Intracellular mechanism responsible for reduced enzyme secretion from camostate-induced hypertrophied pancreas.
Topics: Amylases; Animals; Carbachol; Esters; Gabexate; Guanidines; Hypertrophy; Male; Pancreas; Phosphatidy | 1990 |
Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas.
Topics: Administration, Oral; Animals; Benzodiazepinones; Cholecystokinin; Cholestyramine Resin; Chymotrypsi | 1991 |
Elevation of resting fluid secretion precedes trophic responses in the rat pancreas following a single oral administration of Camostat.
Topics: Administration, Oral; Animals; Biological Transport; Cholecystokinin; Electrolytes; Esters; Gabexate | 1991 |
Subcutaneous administration of the synthetic trypsin inhibitor Foy-305 induces hypertrophy of the exocrine pancreas.
Topics: Administration, Oral; Amylases; Animals; Esters; Female; Gabexate; Guanidines; Hypertrophy; Injectio | 1987 |
Influence of CCK antagonist L-364,718, pancreastatin (33-49) and a somatostatin analogue on camostate-induced rat pancreatic hypertrophy.
Topics: Animals; Benzodiazepinones; Cholecystokinin; Chromogranin A; Devazepide; Esters; Gabexate; Guanidine | 1989 |
Increased CCK-response to proteinase inhibitor feeding after induction of pancreatic hypertrophy in rats.
Topics: Animals; Cholecystokinin; Dose-Response Relationship, Drug; Esters; Female; Gabexate; Guanidines; Hy | 1988 |
Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas.
Topics: Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Esters; Gabexate; Guanidines; Hypertrophy; | 1988 |
[Effect of a specific serine protease inhibitor on the rat pancreas. II. Influence of camostate on the endocrine pancreas].
Topics: Administration, Oral; Animals; Body Weight; Esters; Gabexate; Guanidines; Hypertrophy; Insulin; Insu | 1985 |